EP4155310A1 — Selective estrogen receptor degraders
Assigned to Eli Lilly and Co · Expires 2023-03-29 · 3y expired
What this patent protects
Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R 1 or R 2 is independently selected from Cl, F, -CF 3 , or -CH 3 , and the other is hydrogen, …
USPTO Abstract
Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R 1 or R 2 is independently selected from Cl, F, -CF 3 , or -CH 3 , and the other is hydrogen, and methods for their use are provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.